DELFI Diagnostics

As summer begins, encourage your patients to make a commitment to their health. Low #cancer screening rates are a serious concern, especially for lung cancer, the leading cause of cancer death in the US for both men and women. Talk with your patients about screening today, and encourage the people in your care to spread the word to loved ones who may also be eligible. #DELFI supports #healthcareproviders and #healthcaresystems in their efforts to ensure more eligible people receive the screenings that can save lives. Learn more about how we can support improved #lungcancerscreening rates at: https://bit.ly/4bIh2dY #SummerHealth #CancerAwareness #EarlyDetection

#lungcancer is often asymptomatic in early stages, and early detection leads to better long-term health outcomes. #Lungcancerscreening has a low uptake compared to other #cancer screening: less than 5% of eligible individuals complete lung screening. Raising awareness of this low uptake and making cancer screening options accessible to eligible patients may improve screening rates. #DELFI is committed to supporting #healthcareproviders and #healthcaresystems to improve screening rates among eligible patients. To learn more, visit us at https://bit.ly/3S5lJr0 #earlydetectionsaveslives #LungHealth #HealthcareHeroes

#DELFI is at the forefront of enhancing #lungcancer detection, addressing unmet needs of under-resourced populations. Lung cancer is the leading cause of cancer death in the U.S. and globally. Lung cancer screening is proven to save lives. Still, many individuals in our healthcare system face barriers to screening, such as high costs, lack of insurance, limited access, and logistical challenges. We are committed to ensuring accessible, equitable healthcare for all. #knowledgeispower #earlydetectionsaveslives

#DELFI's pioneering FirstLook Test was created to help make it easier to begin screening patients for #lungcancer, to ensure more eligible patients get the care they need. How does our #LiquidBiopsy for lung cancer work? • The test is conducted via a routine office visit blood draw, making it an accessible first step for more patients • DELFI's technology examines DNA fragments in the blood to scan for patterns associated with lung cancer • It employs machine learning to compare an individual’s cell-free DNA patterns against populations with and without cancer • It's an exceptionally high-performing test, with a Negative Predictive Value (NPV) of 99.8% • Once a clinician receives the results of the test, they can work with their patient to recommend the right next steps, such as an #LDCT Our goal: to help doctors detect lung cancer early, when their patients are still asymptomatic, and #earlystagelungcancer is more responsive to treatment Find out more here: https://lnkd.in/eWi2n6av

🌟 Celebrating Research Appreciation Day 🌟 All progress, big or small, comes through careful and painstaking scientific research. On July 5, #DELFI proudly honors all #cancerresearchers and innovators. Thanks to the tireless efforts of scientists and health professionals, we are able to improve healthcare through advanced diagnostics and therapeutics. Today, we join in celebrating the thousands of #researchers who are profoundly impacting patient care and medical science. We thank you for your dedication and commitment to improving healthcare outcomes worldwide! #ResearchAppreciationDay #CancerResearch #HealthcareInnovation

From the #DELFI family to yours, we wish you a happy, healthy, and safe Fourth of July weekend! Enjoy the festivities, fireworks, cookouts, and quality time with friends and family, as we celebrate American Independence Day, which honors our treasured liberty and democracy.🎆🎉 #IndependenceDay #July4th FirstLook Test

Our FirstLook Test uses advanced machine learning to analyze millions of data points in blood samples to help detect lung cancer. #DELFI derives its analytical power by comparing an individual’s cell-free DNA patterns against populations with and without cancer. The technology uses millions of data points to help identify the possible presence of #cancer. Find out more here: https://lnkd.in/eZGH8iEt

#DELFI CEO Susan Tousi was featured as a panelist at TD @Cowen Inc.'s 3rd Annual Tools/Dx Revolution Conference on June 24. The conference was themed around the collaborative exploration of the essential elements necessary for ongoing industry success, in a year marked by the advent of revolutionary gene therapies, significant AI advancements, and election activity. TD Cowen unites investors, leaders from the Tools and Diagnostics sector, and key figures in capital formation. Other panelists included Katherine Stueland, CEO of GeneDx, Joshua Ofman MD, MSHS, President of GRAIL and Chris Smith, CEO of NeoGenomics Laboratories. We are proud to have Susan included in this group of industry pioneers and this conversation, which aligns with our work to help build solutions in diagnostics that enhance and improve the accessibility of #lungcancerscreening.

Precision Medicine Online interviewed DELFI CMO Peter B. and President & COO Jenn Buechel for an article on #DELFI’s partnership with Indigenous Pact PBC, Inc., a company focused on improving healthcare delivery for Indigenous Americans, on a program bringing our blood-based cell-free DNA fragmentomics assay to aid lung cancer screening, the FirstLook Test, to rural Native American communities. According to Kurt Brenkus, CEO of Indigenous Pact, some rural tribal health systems don't have LDCTs, meaning patients need to travel to another health system, sometimes hours away, to get a lung cancer screening. "American Indians and Alaska Natives have the highest health disparities out of any population in the United States, and cancer is no exception. The fact that this small blood test can be transported into these rural areas and be administered through a primary care setting is a game-changing technology." DELFI’s CMO, Peter B. Bach said "By working with Indigenous Pact, we hope we can help improve lung cancer screening rates in the Native community where lung cancer has the greatest burden." This sentiment echoes DELFI's fundamental goal of making lung cancer screening more accessible to all. Click here to read the article: https://bit.ly/3z97M4P #earlyscreeningsaveslives #lungcancerscreening #indigenouspact #LDCT

Pride is a celebration of one's identity, encompassing gender, race, sexual orientation, and freedom of expression. At #DELFI, we believe that all people are equal. That core belief fires our drive to make critical #lungcancer screening available to all. This #PrideMonth and year-round, #DELFI honors the contributions and spirit of the LGBTQ community. Find out more: https://lnkd.in/duNz3YH